Advances in Biochemistry and Biotechnology (ISSN: 2574-7258)

review article

Reprogram Metabolism of Infiltrated T Cells in Tumor Microenvironment to Improve Immunotherapy Outcomes

Nan Lü, Shanshan Zhang, Yanying Kong, Xiaolin Liang, Laiyou Wang*

Department of Clinical Pharmacy, Guangdong Pharmaceutical University; Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems, Guangzhou, P. R. China

*Corresponding author: Laiyou Wang, Department of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, P. R. China. Email: 

Received Date: 28 August, 2018; Accepted Date: 14 September, 2018; Published Date: 24 September, 2018

1.       Abstract 

Increasing clinical evidences demonstrated that the immune system involved in antigen recognition and cytokine production events may inhibit tumor initiation and progression. Actually, tumors undergoing remission in immunotherapy are largely attributed to Tumor-Infiltrating Lymphocytes (TILs). The quantity, functionality, durability and longevity of TILs harnessed for anti-tumor activity could be important determinants in achieving the efficacy of therapy. The persistence of metabolic qualities of highly-functional T cells is the key to improve immunotherapy outcomes with favorable prognosis. In this review, we focus on metabolic properties of TILs including cellular energetic pathway and discuss the potential approaches and detailed strategies to meticulously modulate infiltrated T cells. Researching and developing chemotherapy drugs armed with immune-enhancing power could transform the medical territory towards cancer. 

2.       Keywords: Combination Therapy; Immuno-metabolism; Metabolic Flux; Tumor-Infiltrating Lymphocytes 

3.       Abbreviations 

TILs                        :               Tumor-Infiltrating Lymphocytes

TCRs      :               T Cell Receptors

IFN-γ      :               Interferon Gamma

TCA       :               Tricarboxylic Acid

OXPHOS               :               Oxidative Phosphorylation

mTOR    :               Mammalian Target of Rapamycin

PI3K       :               Phosphatidylinsitol 3-Kinase

NHL                       :               Non-Hodgkin Lymphoma

AMPK    :               Adenosine Monophosphate-Activated Protein Kinase

CTLs      :               Cytotoxic T Lymphocytes

SRC                        :               Spare Respiratory Capacity

ROS                        :               Reactive Oxygen Species

HIF1α     :               Hypoxia Inducible Factor 1α

VHL                       :               Von Hipple-Lindau

MDSC    :               Myeloid-Derived Suppressor Cells

DCs                        :               Dendritic Cells

IDO                         :               Indoleamine 2,3-Dioxygenase

COX2     :               Cyclooxygenase

MAPK    :               Mitogen-Activated Protein Kinase 

Page Views: 11165717